Physician profile
Christopher M Smith
NPI 1144724477
$5,044.84
in general payments reported to CMS, 2019-2025
25 companies · $2,098 in 2025
The $2,098 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $59.46 · 2023: $882 · 2024: $1,850 · 2025: $2,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,829.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,782.85 | 2021-2025 | Alloderm, Botox, Qulipta |
| Ucb, INC. | $466.93 | 2023-2025 | Fintepla, Briviact, Nayzilam |
| Pfizer INC. | $418.69 | 2023-2025 | |
| Sk Life Science, INC. | $153.40 | 2022-2025 | |
| Argenx US, INC. | $153.17 | 2024-2025 | Vyvgart Hytrulo |
| Lundbeck LLC | $129.44 | 2024-2025 | Vyepti |
| Biogen, INC. | $121.08 | 2024-2025 | Skyclarys |
| Neurelis, INC. | $100.53 | 2021-2024 | Valtoco |
| Emd Serono, INC. | $96.45 | 2021-2023 | Mavenclad |
| Neurocrine Biosciences, INC. | $79.40 | 2022-2024 | Ingrezza |
| Kedrion Biopharma, INC. | $70.73 | 2025 | Kedrab, Koate, Gammaked |
| Alexion Pharmaceuticals, INC. | $67.55 | 2021-2024 | Ultomiris, Soliris |
| Lilly USA, LLC | $63.60 | 2023-2025 | Emgality, Amyvid |
| Vertex Pharmaceuticals Incorporated | $60.11 | 2025 | |
| Amneal Pharmaceuticals LLC | $37.81 | 2025 | Crexont |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.31 | 2025 | Symbravo |
| Vanda Pharmaceuticals INC. | $32.67 | 2025 | Ponvory |
| Catalyst Pharmaceuticals, INC. | $26.16 | 2024 | |
| Acadia Pharmaceuticals INC | $25.98 | 2024 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $24.57 | 2025 | |
| Jazz Pharmaceuticals INC. | $22.76 | 2024 | |
| Eisai INC. | $22.40 | 2025 | |
| Celgene Corporation | $22.27 | 2024 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $18.26 | 2021 | |
| Kyowa Kirin, INC. | $14.72 | 2024 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.